Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study

被引：0

作者：

Moore, Kathleen N.

Sabanathan, Dhanusha

Du, Yiqun

Duan, Huaxin

Li, Xiumin

Wang, Feng

Marathe, Omkar

Yang, Hua

Makker, Vicky

Growdon, Whitfield

Coward, Jim

Zhao, Peng

Liu, Liming

Shi, Rong

Liu, Shengxue

Gu, Wei

Qiu, Yang

Zhu, Zhongyuan

Zhang, Jian

Hamilton, Erika P.

机构：

[1] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Macquarie Univ, Canc Inst, Sydney, Australia

[3] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China

[4] Hunan Prov Peoples Hosp, Changsha, Peoples R China

[5] Linyi Canc Hosp, Shandong, Peoples R China

[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[7] Inst Oncol, Lakewood, CA USA

[8] Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Weill Cornell Med Coll, New York, NY USA

[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[12] ICON Canc Ctr, Brisbane, Australia

[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[14] Dual Biol, Philadelphia, PA USA

[15] Dual Biol, Princeton, NJ USA

[16] Dual Biol, Shanghai, Peoples R China

[17] Dual Biol, Basking Ridge, NJ USA

[18] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China

[19] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China

[20] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3023

引用

页数：1

共 50 条

[41] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Koganemaru, S.
Yoshizuka, N.
Mizuno, S.
Hirai, S.
Yamamoto, N.
ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
[42] A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.
Yachnin, Jeffrey
Ullenhag, Gustav J.
Carneiro, Ana
Nielsen, Dorte
Rohrberg, Kristoffer Staal
Kvarnhammar, Anne Mansson
Dahlman, Anna
Bageman, Erika
Wennersten, Camilla
Russell, Charlotte Astrid
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[43] First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Davis, Elizabeth J.
Martin-Liberal, Juan
Kristeleit, Rebecca
Cho, Daniel C.
Blagden, Sarah P.
Berthold, Dominik
Cardin, Dana B.
Vieito, Maria
Miller, Rowan E.
Dass, Prashanth Hari
Orcurto, Angela
Spencer, Kristen
Janik, John E.
Clark, Jason
Condamine, Thomas
Pulini, Jennifer
Chen, Xuejun
Mehnert, Janice M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
[44] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
Johnson, Melissa
Ulahannan, Susanna
Vandross, Andrae
Park, Haeseong
Faoro, Leo
Faggioni, Raffaella
Li, Jing
Chang, Yu-Lin
Uttamsingh, Shailaja
Tolcher, Anthony
CANCER RESEARCH, 2022, 82 (12)
[45] Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors
Shaheen, Montasser
Markman, Ben
Carducci, Michael
Hurvitz, Sara
Mahadevan, Daruka
Kotasek, Dusan
Goodman, Oscar
Gamelin, Erick
Chow, Vincent
Juan, Gloria
Rasmussen, Erik
Friberg, Gregory R.
Vogl, Florian D.
Desai, Jayesh
CANCER RESEARCH, 2016, 76
[46] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
Harvey, R. Donald
Falchook, Gerald Steven
Naqash, Abdul Rafeh
Kim, Joseph W.
Dowlati, Afshin
Le Bruchec, Yvan
Coudert, Isabelle
Ervin-Haynes, Annette L.
Sommerhalder, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[47] A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale
Santa Gadea, Omar Saavedra
Garralda, Elena
Suzanne Lopez, Juanita
Awad, Mark M.
Stephen Thomas, Jacob
Diane Tiu, Crescens
Morales-Espinosa, Daniela
Raab, Christa
Rehbein, Bettina
Hintzen, Gabriele
Pietzko, Kerstin
Ravenstijn, Paulien
Emig, Michael
El-Khoueiry, Anthony B.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.
Sangha, Randeep S.
Sehn, Laurie Helen
Kuruvilla, John
Weickert, Michael
Mackey, John Robert
Berthiaume, Luc G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
Li, Jian
Zhang, Xinhua
Deng, Yanhong
Wu, Xin
Zheng, Zhichao
Zhou, Yongjian
Cai, Shirong
Zhang, Yanqiao
Zhang, Jun
Tao, Kaixiong
Cui, Yuehong
Cao, Hui
Shen, Kuntang
Yu, Jiren
Zhou, Ye
Ren, Wenxiao
Qu, Chenglin
Zhao, Wanqi
Hu, Jin
Wang, Wei
Yang, Jason
Shen, Lin
ONCOLOGIST, 2023, 28 (02): : 187 - +
[50] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Myint, Han
Shah, Satish
Gutierrez, Martin
Zsiros, Emese
Nelson, Megan
Zeidan, Stephanie
Myrthil, Nadia
Morawski, Aaron
Barbu, Alina
Shaik, Jahangheer
Zhou, Chelsea
Kanellopoulou, Chrysi
Copeland, Ron
Cusumano, Zachary
Flies, Dallas
Langermann, Solomon
Lorusso, Patricia
Odunsi, Kunle
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781

← 1 2 3 4 5 →